TerminatedPhase 3NCT03689244

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

Studying Chronic thromboembolic pulmonary hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Actelion
Principal Investigator
Julian Borissoff, MD, PhD
Actelion
Intervention
Selexipag(drug)
Enrollment
128 enrolled
Eligibility
18-85 years · All sexes
Timeline
20192022

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03689244 on ClinicalTrials.gov

Other trials for Chronic thromboembolic pulmonary hypertension

Additional recruiting or active studies for the same condition.

See all trials for Chronic thromboembolic pulmonary hypertension

← Back to all trials